VivoSeq
Nephrology

Glomerulonephritis

22

Pipeline Programs↗

7

Active Trials↗

16

Companies Involved↗

Glomerulonephritis is an emerging landscape with 22 programs across 16 companies. The most active players are Roche, Kira Pharmacenticals (US), LLC., Bayer. 11 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

11/100

Mech. Concentration

18/100

Completion Rate

86/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

2 programs

Phase 2K

Kira Pharmacenticals (US), LLC.

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2AstraZeneca logo

AstraZeneca

2 programs

Phase 2V

Validus Pharmaceuticals

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

23 of 26 classified programs — the dominant modality here.

12%ALL OTHERSMonoclonal antibody312%

Small molecule leads; the ring shows all 26 classified programs, each share of the total. Modality classified for 100% of 26 pipeline programs.

Analysis

Trial Status

17

clinical trials

Completed6 · 35%
Recruiting5 · 29%
Unknown status3 · 18%
Not yet recruiting2 · 12%
Terminated1 · 6%

Clinical Trials

Trial Activity

17 trials

Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
Recruiting·MMayo Clinic·Phase 2·NCT06295770·20 enrolled
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
Recruiting·Shanghai Henlius Biotech logoShanghai Henlius Biotech·Phase 2·NCT07038382·24 enrolled
Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
Recruiting·MMayo Clinic·Phase 2·NCT05654506·40 enrolled
Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3
Recruiting·TThe First Affiliated Hospital of Dalian Medical University·Phase 4·NCT04263922·466 enrolled
Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis
Recruiting·—·Phase 2·NCT06835322·100 enrolled
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis
Not yet recruiting·KKira Pharmacenticals (US), LLC.·Phase 2·NCT05517980·52 enrolled
Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous
Not yet recruiting·CCentre Hospitalier Universitaire de Nice·Phase 2·NCT07096986·20 enrolled
Empagliflozin in Patients With Glomerulonephritis
Completed·KKasr El Aini Hospital·Phase 3·NCT05283057·50 enrolled
Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
Completed·MMayo Clinic·Phase 2·NCT02197767·11 enrolled
Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis
Completed·UUniversity of Turin, Italy·Phase 4·NCT06680349·21 enrolled
Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis
Completed·UUniversity Magna Graecia·Phase 4·NCT01115426·20 enrolled
HSP-glomerulonephritis Trial: MP vs CyA
Completed·OOulu University Hospital·Phase 4·NCT00425724·20 enrolled
Evaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis
Completed·NNational Taiwan University Hospital·N/A·NCT00154661·20 enrolled
Efficacy of Pentoxifylline on Rapidly Progressive Glomerulonephritis
Terminated·NNational Taiwan University Hospital·Phase 3·NCT00354198·7 enrolled
Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis(HBV-GN)
Unknown status·GGuangdong Provincial People's Hospital·Phase 4·NCT03062813·112 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)